JPS61197579A - イソシリビン不含のシリビニンの製造法 - Google Patents
イソシリビン不含のシリビニンの製造法Info
- Publication number
- JPS61197579A JPS61197579A JP60261630A JP26163085A JPS61197579A JP S61197579 A JPS61197579 A JP S61197579A JP 60261630 A JP60261630 A JP 60261630A JP 26163085 A JP26163085 A JP 26163085A JP S61197579 A JPS61197579 A JP S61197579A
- Authority
- JP
- Japan
- Prior art keywords
- weight
- parts
- ethyl acetate
- vacuo
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 title claims description 81
- 238000004519 manufacturing process Methods 0.000 title claims description 6
- 239000003814 drug Substances 0.000 title description 6
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 claims description 72
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 60
- 235000014899 silybin Nutrition 0.000 claims description 60
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 48
- 229950000628 silibinin Drugs 0.000 claims description 48
- FDQAOULAVFHKBX-UHFFFAOYSA-N Isosilybin A Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC(=CC=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 FDQAOULAVFHKBX-UHFFFAOYSA-N 0.000 claims description 18
- 239000000047 product Substances 0.000 claims description 15
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- VLGROHBNWZUINI-UHFFFAOYSA-N Silybin Natural products COc1cc(ccc1O)C2OC3C=C(C=CC3OC2CO)C4Oc5cc(O)cc(O)c5C(=O)C4O VLGROHBNWZUINI-UHFFFAOYSA-N 0.000 claims description 12
- 229940043175 silybin Drugs 0.000 claims description 12
- 239000012141 concentrate Substances 0.000 claims description 11
- 239000002244 precipitate Substances 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 11
- 235000013399 edible fruits Nutrition 0.000 claims description 10
- 239000000725 suspension Substances 0.000 claims description 10
- 238000009835 boiling Methods 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 238000000967 suction filtration Methods 0.000 claims description 7
- FDQAOULAVFHKBX-KMRPREKFSA-N (+)-Isosilybin A Natural products C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC(=CC=C3O2)[C@@H]2[C@@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 FDQAOULAVFHKBX-KMRPREKFSA-N 0.000 claims description 6
- FDQAOULAVFHKBX-HKTJVKLFSA-N (2r,3r)-3,5,7-trihydroxy-2-[(2r,3r)-2-(4-hydroxy-3-methoxyphenyl)-3-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2,3-dihydrochromen-4-one Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC(=CC=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 FDQAOULAVFHKBX-HKTJVKLFSA-N 0.000 claims description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- KDMGQPNVTKUNHV-UHFFFAOYSA-N Isosilybin Natural products C1=C(O)C(OC)=CC=C1C1C(CO)OC2=CC=C(C3C(C(=O)C4=C(O)C=C(O)C=C4O3)O)C=C2O1 KDMGQPNVTKUNHV-UHFFFAOYSA-N 0.000 claims description 6
- 208000019423 liver disease Diseases 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 239000003208 petroleum Substances 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 239000013040 bath agent Substances 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- KGDGIOVJEIIWFE-UHFFFAOYSA-N 3-hydroxy-3-phenyl-4h-chromen-2-one Chemical compound C1C2=CC=CC=C2OC(=O)C1(O)C1=CC=CC=C1 KGDGIOVJEIIWFE-UHFFFAOYSA-N 0.000 claims 2
- 241000320380 Silybum Species 0.000 claims 2
- 235000011869 dried fruits Nutrition 0.000 claims 2
- 238000001704 evaporation Methods 0.000 claims 2
- 230000008020 evaporation Effects 0.000 claims 2
- 229920002635 polyurethane Polymers 0.000 claims 2
- 239000004814 polyurethane Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000023753 dehiscence Effects 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 239000008024 pharmaceutical diluent Substances 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 231100000167 toxic agent Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 239000003440 toxic substance Substances 0.000 claims 1
- 229960004245 silymarin Drugs 0.000 description 12
- 235000017700 silymarin Nutrition 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000003610 charcoal Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- -1 ethyl ethyl Chemical group 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 230000005976 liver dysfunction Effects 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 235000021419 vinegar Nutrition 0.000 description 2
- 239000000052 vinegar Substances 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 241001070941 Castanea Species 0.000 description 1
- 235000014036 Castanea Nutrition 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000233457 Mesophyllum Species 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 241000861914 Plecoglossus altivelis Species 0.000 description 1
- 229910052777 Praseodymium Inorganic materials 0.000 description 1
- 241001474791 Proboscis Species 0.000 description 1
- BOTDANWDWHJENH-UHFFFAOYSA-N Tetraethyl orthosilicate Chemical compound CCO[Si](OCC)(OCC)OCC BOTDANWDWHJENH-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000003679 aging effect Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000012822 chemical development Methods 0.000 description 1
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 229960003750 ethyl chloride Drugs 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 210000000554 iris Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- PUDIUYLPXJFUGB-UHFFFAOYSA-N praseodymium atom Chemical compound [Pr] PUDIUYLPXJFUGB-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3442641 | 1984-11-22 | ||
| DE3442641.8 | 1985-10-23 | ||
| DE3537656.2 | 1985-10-23 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP3009169A Division JPH0678228B2 (ja) | 1984-11-22 | 1991-01-29 | イソシリビン不含のシリビニンを含有する医薬調剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS61197579A true JPS61197579A (ja) | 1986-09-01 |
| JPH0339506B2 JPH0339506B2 (enrdf_load_stackoverflow) | 1991-06-14 |
Family
ID=6250904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP60261630A Granted JPS61197579A (ja) | 1984-11-22 | 1985-11-22 | イソシリビン不含のシリビニンの製造法 |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JPS61197579A (enrdf_load_stackoverflow) |
| DD (2) | DD262429A1 (enrdf_load_stackoverflow) |
| ZA (1) | ZA858935B (enrdf_load_stackoverflow) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012526739A (ja) * | 2009-05-14 | 2012-11-01 | エウロメッド・エセ・ア | ウイルス性肝炎の治療のための非晶質シリビニン |
-
1985
- 1985-11-20 DD DD30516385A patent/DD262429A1/de not_active IP Right Cessation
- 1985-11-20 DD DD28304385A patent/DD258231A1/de not_active IP Right Cessation
- 1985-11-21 ZA ZA858935A patent/ZA858935B/xx unknown
- 1985-11-22 JP JP60261630A patent/JPS61197579A/ja active Granted
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012526739A (ja) * | 2009-05-14 | 2012-11-01 | エウロメッド・エセ・ア | ウイルス性肝炎の治療のための非晶質シリビニン |
| JP2016026166A (ja) * | 2009-05-14 | 2016-02-12 | エウロメッド・エセ・ア | ウイルス性肝炎の治療のための非晶質シリビニン |
Also Published As
| Publication number | Publication date |
|---|---|
| DD258231A1 (de) | 1988-07-13 |
| DD262429A1 (de) | 1988-11-30 |
| ZA858935B (en) | 1986-08-27 |
| JPH0339506B2 (enrdf_load_stackoverflow) | 1991-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1280369C (en) | Pharmaceutical with anti-tumor effect | |
| US4708949A (en) | Therapeutic composition from plant extracts | |
| US4795742A (en) | Therapeutic composition from plant extracts | |
| US4871763A (en) | Method of treating liver diseases using pure silibinin | |
| EP0200169B1 (en) | Pharmaceutical composition for cure and prevention of cardiovascular disease and method of preparing the same | |
| US5108750A (en) | Pharmaceutical compositions for reducing hyperlipidemia and platelet-aggregation | |
| CA1106285A (en) | Process for obtaining a natural polar fraction having anti-psoriatic activity | |
| JPH07330596A (ja) | 抗腫瘍剤 | |
| JPS61197579A (ja) | イソシリビン不含のシリビニンの製造法 | |
| US4898882A (en) | Resistance imparting agent for cold syndrome of low pulmonary function patients | |
| JP3164455B2 (ja) | 角層修復促進剤 | |
| CN112972473B (zh) | 一种用于治疗肿瘤放化疗消化道不良反应的药物及其制备方法 | |
| US3832343A (en) | Process for obtaining an extract of arnica montana | |
| JPH06183959A (ja) | 血行促進剤 | |
| SU1456013A3 (ru) | Способ получени силибинина | |
| JPS60193996A (ja) | 側柏葉から止血活性物質を抽出する方法、及びそれを含有する止血剤 | |
| JPS60120879A (ja) | 早蓮草より止血活性物質を製造する方法、及び該成分を含む止血剤 | |
| JPH04275224A (ja) | 痴呆症治療剤 | |
| JP3072584B2 (ja) | 皮膚角質層水分量増加剤 | |
| JPS62240621A (ja) | 止血剤 | |
| JPS5959622A (ja) | ア−モンド、アンズ又はニワウメの種子から得られる生物活性蛋白質 | |
| CN120022236A (zh) | 一种乳果糖口服溶液 | |
| CA1073816A (en) | Cholesterol derivative-based medicaments acting on bio-protective mechanisms | |
| Grollman et al. | Effects of renal extract on hypertension | |
| Krause | Studies in Immunity to Tuberculosis: Concerning the General Tuberculin Reaction |